Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 8.59% | < 30% | Pass |
| Interest-bearing investments / market cap | 0% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from MANKIND should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
Slightly positive 3–6 month returns with a small 1-month decline and moderate distance from the 52-week high point to a consolidating range. The 50-day above 200-day shows a still-supportive longer-term structure.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.